Atlas Trials

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Clinical trial NCT06997068 · RECRUITING

Trial details

NCT number
NCT06997068
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Oral Cavity CarcinomaRecurrent Oral Cavity CarcinomaStage IVC Lip and Oral Cavity Cancer AJCC v8Head and Neck CancerHypopharynx CancerOropharynx CancerClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Metastatic Hypopharyngeal CarcinomaMetastatic Laryngeal CarcinomaMetastatic Malignant Head and Neck NeoplasmMetastatic Oropharyngeal CarcinomaRecurrent Hypopharyngeal Carcinoma
Start date
2025-07-09
Primary completion
2028-06-30
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.